| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | 218 | Edison Investment Research | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | |
| Do | Metlen (ASE: MYTIL) FY24 Results | 159 | Edison Investment Research | Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus... ► Artikel lesen | |
| Do | Mendus - Vididencel on track in AML going into 2025 | 164 | Edison Investment Research | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
| Do | Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results | 225 | Edison Investment Research | Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 338 |
| RHEINMETALL | 302 |
| BYD | 272 |
| RENK GROUP | 232 |
| TESLA | 211 |
| SUPER MICRO COMPUTER | 197 |
| BAYER | 182 |
| TUI | 181 |
| THYSSENKRUPP | 176 |
| NOVO NORDISK | 166 |
| PALANTIR TECHNOLOGIES | 164 |
| ALIBABA | 136 |
| XIAOMI | 122 |
| INTEL | 120 |
| EVOTEC | 112 |
| NEL | 112 |
| PROSIEBENSAT.1 | 109 |
| RWE | 109 |
| MERCEDES-BENZ | 102 |
| BLOCK | 97 |
| AMAZON | 92 |
| DEUTSCHE BANK | 91 |
| D-WAVE QUANTUM | 88 |
| ALLIANZ | 87 |
| DEUTSCHE TELEKOM | 85 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
